SCHEMBL2043458

SCHEMBL2043458

CCOC(=O)/C=C/c1ccc(OCC)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.71
CA1 P00915 1/20 0.71
CA2 P00918 1/20 0.71
CA7 P43166 1/20 0.71
CA9 Q16790 1/20 0.71
CA14 Q9ULX7 1/20 0.71
MAOB P27338 9/20 0.64
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
MAPT P10636 2/20 0.61
KDM4E B2RXH2 1/20 0.61
ALDH1A1 P00352 1/20 0.61
HTT P42858 1/20 0.61
CYP3A4 P08684 1/20 0.61
KMT2A Q03164 1/20 0.61
TTR P02766 1/20 0.60
DPP4 P27487 1/20 0.60
ABCG2 Q9UNQ0 1/20 0.60
TP53 P04637 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959915 1.00 CA12 (0.71) CA12CA1CA2CA7CA9
SCHEMBL14634503 0.90 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL14634505 0.90 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL13957401 0.89 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL5059085 0.89 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL10939791 0.89 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL12976848 0.89 TAS1R3 (0.60) CA12CA1CA2CA7CA9
SCHEMBL19244429 0.89 APP (0.61) CA12CA1CA2CA7CA9
SCHEMBL19244431 0.89 APP (0.61) CA12CA1CA2CA7CA9
SCHEMBL19244313 0.89 CA12 (0.65) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115135307-A Carrier for cell delivery 株式会社ITO 2022-09-30 CN claimed
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US claimed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US claimed
EP-2328938-B1 RADICALLY FUNCTIONALIZED OLEFIN-BASED POLYMER WITH REDUCED MOLECULAR WEIGHT CHANGE AND METHOD DOW GLOBAL TECHNOLOGIES LLC (US) 2015-04-01 EP claimed
CN-102216337-B Free radical functionalized olefin-based polymers with reduced molecular weight variation and methods DOW GLOBAL TECHNOLOGIES INC 2013-11-13 CN claimed
CN-102216337-A Free radical functionalized olefin-based polymers with reduced molecular weight variation and methods DOW GLOBAL TECHNOLOGIES INC 2011-10-12 CN claimed
US-20110172368-A1 Radically Functionalized Olefin-Based Polymer with Reduced Molecular Weight Change and Method DOW GLOBAL TECHNOLOGIES INC. 2011-07-14 US claimed
EP-2328938-A1 RADICALLY FUNCTIONALIZED OLEFIN-BASED POLYMER WITH REDUCED MOLECULAR WEIGHT CHANGE AND METHOD Dow Global Technologies LLC (US) 2011-06-08 EP claimed
WO-2010036642-A1 RADICALLY FUNCTIONALIZED OLEFIN-BASED POLYMER WITH REDUCED MOLECULAR WEIGHT CHANGE AND METHOD DOW GLOBAL TECHNOLOGIES INC. (US) 2010-04-01 WO claimed
US-20250295566-A1 DIESTER HAIR STYLING FORMULATIONS, AND USES THEREOF Chembeau LLC 2025-09-25 US disclosed
US-20250248913-A1 HAIR TREATMENT FORMULATIONS AND USES THEREOF Chembeau LLC 2025-08-07 US disclosed
US-20250177270-A1 DIESTER COSMETIC FORMULATIONS AND USES THEREOF Chembeau LLC 2025-06-05 US disclosed
US-12285508-B2 Hair treatment formulations and uses thereof Chembeau LLC (US) 2025-04-29 US disclosed
US-12214065-B2 Diester cosmetic formulations and uses thereof Chembeau LLC (US) 2025-02-04 US disclosed
WO-2005074881-A2 METHOD FOR STABILIZING OIL-BASED THICKENING GEL COMPOSITION SHOWA DENKO K.K. (JP) 2005-08-18 WO disclosed
WO-2005034903-A1 AGENT FOR SKIN EXTERNAL USE CONTAINING SALT OF ASCORBIC ACID DERIVATIVE, METHOD FOR STABILIZING THE AGENT FOR SKIN EXTERNAL USE, AND STABILIZER SHOWA DENKO K.K. (JP) 2005-04-21 WO disclosed
WO-2005020950-A1 COSMETIC COMPOSITION COMPRISING A AND A LIPOPEPTIDE SHOWA DENKO K.K. (JP) 2005-03-10 WO disclosed
US-20040219125-A1 Oily thickened gel-like composition, emulsified composition using the composition and preparation method thereof SHOWA DENKO K.K. (JP) 2004-11-04 US disclosed
EP-1414389-A1 OILY THICKENED GEL-LIKE COMPOSITION, EMULSIFIED COMPOSITION USING THE COMPOSITION, AND PREPARATION METHOD THEREOF Showa Denko K.K. (JP) 2004-05-06 EP disclosed
WO-2003013446-A1 OILY THICKENED GEL-LIKE COMPOSITION, EMULSIFIED COMPOSITION USING THE COMPOSITION AND PREPARATION METHOD THEREOF SHOWA DENKO K.K. (JP) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS XPA, MEP1A, EED CA12 4873/4885CA1 4879/4885CA2 4877/4885
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells XPA, MEP1A, EED CA12 4873/4885CA1 4879/4885CA2 4877/4885
US-20040219125-A1 Oily thickened gel-like composition, emulsified composition using the composition and preparation method thereof CUTA, LIPC, LIPA CA12 3950/4885CA1 4618/4885CA2 4508/4885
US-12214065-B2 Diester cosmetic formulations and uses thereof DAGLA, CYP19A1, CYP51A1 CA12 607/4885CA1 3300/4885CA2 2399/4885
US-20250295566-A1 DIESTER HAIR STYLING FORMULATIONS, AND USES THEREOF SUCLG1, SMS, SRM CA12 73/4885CA1 299/4885CA2 136/4885
US-20250248913-A1 HAIR TREATMENT FORMULATIONS AND USES THEREOF FHIT, SUCLG1, TES CA12 1328/4885CA1 1805/4885CA2 918/4885
US-12285508-B2 Hair treatment formulations and uses thereof FHIT, SUCLG1, TES CA12 1328/4885CA1 1805/4885CA2 918/4885
US-20250177270-A1 DIESTER COSMETIC FORMULATIONS AND USES THEREOF DAGLA, CYP19A1, CYP51A1 CA12 607/4885CA1 3300/4885CA2 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.